Clinical trials
Amyloidosis clinical trials
Below are recruiting amyloidosis clinical trials, each written for real people, not researchers. We’re tracking 155 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07388602RecruitingPhase 3
New drug combo for newly diagnosed AL amyloidosis
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT01408225Recruiting
Myeloma and amyloidosis patient data and sample registry
This study collects health information and, if needed, samples from people diagnosed with certain blood disorders related to plasma cells. Sharing your information may help researchers better understand these diseases and improve future care.
Columbus, OhioAges 18 years+ - NCT02798705Recruiting
Testing heart tiny blood vessel function in amyloidosis
This study measures how well the heart’s tiny blood vessels work in people with cardiac amyloidosis, using special heart testing. It may help doctors understand the disease better and improve how patients are evaluated over time.
SeoulAges 18–85 - NCT07435168Recruiting
Chest pain and hidden cardiac amyloidosis study
This study looks for signs of a condition called cardiac amyloidosis in people who have chest pain but no blocked heart arteries. It aims to find hidden cases that might be missed with standard tests.
CopenhagenAges 65 years+ - NCT07448779Recruiting
A study on N-glycosylation and its role in AL amyloidosis
This research study looks at how certain sugar molecules (N-glycosylation) on proteins may play a role in a disease called AL amyloidosis. Researchers will study blood samples from people with related plasma cell disorders to learn more about these sugars, which could help with diagnosis and treatment.
Pavia, PVAges 18–99 - NCT07448935Recruiting
Understanding a gene's role in AL amyloidosis and POEMS
This study looks at how a specific gene (IGLV1-44) affects two rare diseases: AL amyloidosis and POEMS syndrome. It involves a blood draw and possibly a bone marrow sample to learn more about how the gene works in these conditions.
PaviaAges 18–99 - NCT07583823Recruiting
Higher-Rate Pacing for Heart Amyloid Disease
This study tests whether pacing your heart at a faster rate helps people with cardiac amyloidosis (a condition where abnormal protein builds up in the heart). If you have a pacemaker and cardiac amyloidosis, this research might help doctors understand the best pacing settings for you.
Minneapolis, MinnesotaAges 18 years+ - NCT07638683RecruitingPhase 2
Teclistamab and Daratumumab for New Multiple Myeloma With Amyloidosis
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
ShanghaiAges 18 years+ - NCT07644325Recruiting
Comparing Two Biopsy Methods for Carpal Tunnel Amyloidosis
This study compares two small tissue samples taken during carpal tunnel surgery to see which method best detects a protein disease (transthyretin amyloidosis) that can affect nerves and the heart. If you have carpal tunnel syndrome and are having surgery, this research may help doctors diagnose related heart or nerve problems earlier.
MontpellierAges 18 years+ - NCT06679946Enrolling by invitationPhase 3
Study of Vutrisiran for heart condition from TTR amyloidosis
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
Phoenix, ArizonaAges 18 years+ - NCT06412432Enrolling by invitation
Exercise and rehab for heart amyloidosis
This study tests whether a supervised exercise and rehabilitation program can help people with a specific type of heart amyloidosis (ATTRwt) feel better and improve their heart function. It may be a good fit if you have stable heart failure and can safely exercise.
NaplesAges 18 years+ - NCT04210791Enrolling by invitation
Stem cell transplant using your own cells for AL amyloidosis
This trial tests whether an autologous stem cell transplant (using your own stem cells) can help people with newly diagnosed AL amyloidosis. It may be offered to help your body reset abnormal disease-producing cells, based on your health and test results.
Nanjing, JiangsuAges 18–75 - NCT04849754Recruiting
Monitoring heart amyloidosis with a special scan
This study looks at how a type of heart condition called transthyretin cardiac amyloidosis changes over time, using a special imaging test called a bone scan. The goal is to see if the scan can help track the disease and potentially improve care.
LilleAges 18 years+ - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Phoenix, ArizonaAges 18 years+ - NCT07398950Enrolling by invitation
AI screening for a heart condition called ATTR-CM
This study uses artificial intelligence (AI) to look at your heart tests (ECG and echo) and find people who might have a specific heart muscle disease called ATTR-CM. The goal is to catch it earlier so treatment can start sooner.
New Haven, ConnecticutAges 18 years+ - NCT06101108Recruiting
Early heart screening in back surgery patients
This trial checks people having back surgery for spinal stenosis to see if they have an early sign of heart amyloidosis (a protein buildup in the heart). The goal is to find this condition early so it can be treated before it causes problems.
BrugesAges 60 years+ - NCT04935021RecruitingPhase 4
Study of ATTR cardiac amyloidosis in patients and gene carriers
This study looks at ATTR cardiac amyloidosis (a condition caused by an inherited protein change) in people who have the disease or carry the gene. It may help researchers learn how ATTR affects the heart and how care can be improved.
Hangzhou, ZhejiangAges 18–80 - NCT07448623RecruitingPhase 1
Testing coramitug for ATTR amyloid heart disease
This study tests a new medication called coramitug to see if it can reduce abnormal protein deposits in the heart. You will have special PET/CT scans to measure how the drug affects these deposits.
GroningenAges 60 years+ - NCT04924998Recruiting
Study for AL-CM treatment in adults at one hospital
This study is looking at a treatment approach for people diagnosed with AL-CM at a specific hospital. It may help researchers understand whether the treatment is safe and effective for patients like you.
Hangzhou, ZhejiangAges 18–80 - NCT07306949RecruitingPhase 4
Acoramidis for transthyretin cardiac amyloidosis
This trial tests a new medicine called acoramidis for people with a heart condition caused by a protein called transthyretin. It includes people who are newly diagnosed or who are already taking another drug (tafamidis) and may benefit from switching. The goal is to see how well acoramidis works and how it affects heart-related measures.
Bunkyō CityAges 18–100 - NCT07298044RecruitingPhase 4
Switching from tafamidis to acoramidis for heart condition
This study checks how levels of a protein called transthyretin change in your blood when you switch from tafamidis to acoramidis. It is for people with a specific type of heart disease caused by abnormal protein buildup.
Sankt Pölten, Lower AustriaAges 18–90 - NCT07205666Recruiting
Eplontersen pregnancy and breastfeeding safety study
This study tracks the safety of eplontersen during pregnancy and breastfeeding by collecting reports from people who have taken it. It helps doctors understand any risks to the baby or mother.
FrankfurtAges Any age - NCT05697861Enrolling by invitation
Follow-up study for people previously treated with NTLA-2001
This study checks how people are doing long-term after receiving NTLA-2001 in an Intellia clinical trial. If you previously took part and agree to be followed, this may help the researchers understand lasting safety and effects.
ParisAges 18 years+ - NCT07560306RecruitingPhase 3
New Heart Scan to Detect Blood Clots in Amyloid Heart Disease
This study tests a new type of imaging scan ([64Cu]FBP8 PET) to detect blood clots that may form in the heart's left atrial appendage (a small pouch in the heart) in patients with amyloid cardiomyopathy (a disease where abnormal protein builds up in heart muscle) who also have irregular heartbeat. The scan may help doctors catch clots earlier and prevent strokes.
Boston, MassachusettsAges 18 years+
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for amyloidosis?
- Yes. Clin2 currently lists 155 recruiting amyloidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a amyloidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a amyloidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.